Abstract 15420: Resolving a Controversy: Inhibition of Cardiac Ryanodine Receptors is the Principal Mechanism of Antiarrhythmic Action of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia

Dmytro O. Kryshtal,Daniel J. Blackwell,Christian L Egly,Abigail N Smith,Suzanne M. Batiste,Jeffrey N. Johnston,Derek R. Laver,Björn C. Knollmann

Abstract 15420: Resolving a Controversy: Inhibition of Cardiac Ryanodine Receptors is the Principal Mechanism of Antiarrhythmic Action of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia

2020

Dmytro O. Kryshtal
Daniel J. Blackwell
Christian L Egly
Abigail N Smith
Suzanne M. Batiste
Jeffrey N. Johnston
Derek R. Laver
Björn C. Knollmann

Rationale: The class Ic antiarrhythmic drug flecainide prevents ventricular tachyarrhythmia in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT), a disease caused by hypera...

Keywords:

Internal medicine
Ion channel
Medicine
Flecainide
Class Ic antiarrhythmic drug
Catecholaminergic polymorphic ventricular tachycardia
Ryanodine receptor
Ventricular tachyarrhythmia
Cardiology
principal mechanism
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations